SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $392 | -30.6% | 27,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $565 | -64.1% | 27,000 | -63.9% | 0.00% | 0.0% |
| Q1 2023 | $1,575 | +148.8% | 74,700 | +200.0% | 0.00% | -33.3% |
| Q4 2022 | $633 | -99.9% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $598,000 | +24.8% | 24,900 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $479,000 | +17.4% | 24,900 | +6.0% | 0.00% | +100.0% |
| Q1 2022 | $408,000 | +3038.5% | 23,500 | +1466.7% | 0.00% | – |
| Q4 2017 | $13,000 | -23.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2017 | $17,000 | -15.0% | 1,500 | 0.0% | 0.00% | – |
| Q2 2017 | $20,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q1 2017 | $20,000 | +100.0% | 1,500 | 0.0% | 0.00% | – |
| Q4 2016 | $10,000 | -54.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2016 | $22,000 | +46.7% | 1,500 | -6.2% | 0.00% | – |
| Q2 2016 | $15,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |